BBIO Stock Forecast & Price Target

BridgeBio Pharma has demonstrated robust commercial momentum for its lead drug, Attruby (acoramidis), with patient prescriptions increasing from 430 to 1,028 and unique prescribers expanding to 516 in a short period, highlighting strong market demand. The favorable outcomes from the phase 3 ATTRibute-CM trial, which showed significant improvements in patient survival, quality of life, and reduced hospitalizations, are likely driving this acceleration in uptake. Additionally, the anticipated entry of competing therapies may further enhance market awareness and diagnosis rates, potentially supporting long-term growth in the ATTR-CM segment.

BridgeBio Pharma faces several fundamental challenges that contribute to a negative outlook on its stock. These challenges include a lack of necessary commercial infrastructure to effectively support the launch of its lead drug, acoramidis, and ongoing legislative pressures related to drug pricing, which could affect profitability. Additionally, the company has struggled to secure productive partnerships for international distribution, has not obtained crucial non-dilutive funding, and presents potential medium- to long-term dilution risks for investors.